USE OF CD36 INHIBITOR IN PREPARING MEDICAMENT FOR INHIBITING SCARRING AFTER SPINAL CORD INJURY

The present invention provides use of a CD36 inhibitor in preparing a medicament for inhibiting scarring after spinal cord injury. The present invention relates to the field of biotechnology, and particularly to use of a CD36 inhibitor in a medicament for repairing nerve injury. According to the present invention, in a spinal cord T10 semi-transection model, CD36 inhibitor salvianolic acid B was intraperitoneally administered at 100 mL at three doses (50, 100, and 200 μg/mL). After 8 weeks, significantly inhibited fibrotic scarring induced by the local aggregation of fibroblasts around the injury was observed, as well as promoted local vascular regeneration at the injury. The present invention helps understand the importance of the plant extract in the nerve injury repair process, and provides a new target for treatment after nerve injury. La présente invention concerne l'utilisation d'un inhibiteur de CD36 dans la préparation d'un médicament pour inhiber la cicatrisation après une lésion de la moelle épinièr